<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<pubmed-document>
<record>
<header>
<identifier>26047999</identifier>
<setSpec>1405-9940</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:author>Sandoval-Zárate, Julio</dc:author>
<dc:author>Beltrán-Gámez, Miguel E</dc:author>
<dc:author>Pulido, Tomás</dc:author>
<dc:description xml:lang="en">In experimental and clinical cardiology, phosphodiesterase type 5 (PDE-5) inhibitors have brought scientific interest as a therapeutic tool in pulmonary arterial hypertension (PAH) management in recent years. Phosphodiesterases are a superfamily of enzymes that inactivate cyclic adenosine monophosphate and cyclic guanosine monophosphate, the second messengers of prostacyclin and nitric oxide. The rationale for the use of PDE-5 inhibitors in PAH is based on their capacity to overexpresss the nitric oxide pathway pursued inhibition of cyclic guanosine monophosphate hydrolysis. By increasing cyclic guanosine monophosphate levels it promotes vasodilation, antiproliferative and pro-apoptotic effects that may reverse pulmonary vascular remodeling. There is also evidence that these drugs may directly enhance right ventricular contractility through an increase in cyclic adenosine monophosphate mediated by the inhibition of the cyclic guanosine monophosphate -sensitive PDE-3. Sildenafil, tadalafil and vardenafil are 3 specific PDE-5 inhibitors in current clinical use, which share similar mechanisms of action but present some significant differences regarding potency, selectivity for PDE-5 and pharmacokinetic properties. Sildenafil received approval in 2005 by the Food and Drug Administration and the European Medicines Agency and tadalafil in 2009 by the Food and Drug Administration and the European Medicines Agency for the treatment of PAH in patients classified as NYHA/WHO functional class II and III. In Mexico, sildenafil and tadalafil were approved by Comisión Federal de Protección contra Riesgos Sanitarios for this indication in 2010 and 2011, respectively.</dc:description>
<dc:type>English Abstract</dc:type>
<dc:language>es</dc:language>
<dc:subject>Inhibidores de fosfodiesterasa-5</dc:subject>
<dc:subject>Hipertensión pulmonar</dc:subject>
<dc:subject>Phosphodiesterase-5 inhibitors</dc:subject>
<dc:subject>Mexico</dc:subject>
<dc:subject>México</dc:subject>
<dc:subject>Pulmonary hypertension</dc:subject>
<dc:date>2015 Jul-Sep </dc:date>
<dc:title xml:lang="es">Inhibidores de fosfodiesterasa-5 para el tratamiento de la hipertensión arterial pulmonar.</dc:title>
<dc:title xml:lang="en">[Phosphodiesterase-5 inhibitors for the treatment of pulmonary arterial hypertension].</dc:title>
<dc:publisher>Archivos de cardiologia de Mexico</dc:publisher>
</metadata>
</record>
</pubmed-document>
